Journal of Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register today!

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norwood, D. A.
Right arrow Articles by Norwood, R. M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Pharmacy Practice, Vol. 17, No. 4, 239-250 (2004)
DOI: 10.1177/0897190004269201
© 2004 SAGE Publications

Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil

Daryl A. Norwood, PharmD

Department of Clinical Pharmacy, Florida A&M University (FAMU)-Miami

Nathaniel E. Eraikhuemen, PharmD

Department of Clinical Pharmacy, Florida A&M University (FAMU)-Miami, Nathan.Eraikhuemen{at}famu.edu

Margareth Larose-Pierre, PharmD

Department of Clinical Pharmacy, Florida A&M University (FAMU)-Miami

Evans Branch, III, PharmD

Department of Clinical Pharmacy, Florida A&M University (FAMU)-Miami

Rhonda M. Norwood

College of Pharmacy, Florida A&M University (FAMU) - Miami.

Erectile dysfunction (ED) affects more than 150 million men and their partners throughout the world. Sildenafil, the first oral phosphodiesterase-type 5 (PDE-5) inhibitor approved for the treatment of ED, has led to the discovery of 2 more products in this class, with tadalafil being the latest. Tadalafil has proven to be well tolerated in various clinical studies and has demonstrated effectiveness in men with mild to severe ED, regardless of severity, etiology, or age. One major characteristic that may distinguish tadalafil from other oral PDE-5 inhibitors is its extensive duration of effect. Tadalafil has a therapeutic duration of up to 36 hours that may allow patients to engage in sexual activity at their own convenience rather than in a limited time period. This, along with other clinical and practical advantages, should make tadalafil an attractive alternative to currently available treatments options. This article summarizes the pharmacology, pharmacokinetics, adverse effects, and clinical efficacy of tadalafil.

Key Words: Erectile dysfunction • sildenafil • tadalafil • pharmacokinetics • pharmacology • drug interactions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?